{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:14:11Z","timestamp":1791828851795,"version":"4.3.4"},"reference-count":119,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.autrev.2025.103758","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T23:18:03Z","timestamp":1737847083000},"page":"103758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Assessment and management for latent tuberculosis before advanced therapies for immune-mediated inflammatory diseases: A comprehensive review"],"prefix":"10.1016","volume":"24","author":[{"given":"Daya Krishna","family":"Jha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinkalben","family":"Kakadiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipankar","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103758_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3899\/jrheum.091462","article-title":"Pathophysiology and pathogenesis of immune-mediated inflammatory diseases: commonalities and differences","volume":"85","author":"Rahman","year":"2010","journal-title":"J Rheumatol Suppl"},{"issue":"10","key":"10.1016\/j.autrev.2025.103758_bb0010","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: past, present and future","volume":"21","author":"McInnes","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103758_bb0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2025.103758_bb0020","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nri.2017.69","article-title":"Heterogeneity in tuberculosis","volume":"17","author":"Cadena","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103758_bb0025","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nri3211","article-title":"Revisiting the role of the granuloma in tuberculosis","volume":"12","author":"Ramakrishnan","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000043","article-title":"Is adipose tissue a place for Mycobacterium tuberculosis persistence?","volume":"1","author":"Neyrolles","year":"2006","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.autrev.2025.103758_bb0035","article-title":"Distinct Persistence Fate of Mycobacterium tuberculosis in Various Types of Cells mSystems","volume":"6","author":"Chen","year":"2021"},{"issue":"10","key":"10.1016\/j.autrev.2025.103758_bb0040","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/rheumatology\/keu172","article-title":"Risk of TB in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2025.103758_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of TB in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0050","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s12876-021-01973-5","article-title":"Risk and characteristics of TB after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea","volume":"21","author":"Lee","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103758_bb0055","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/07853890.2014.941919","article-title":"Higher risk of TB reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials","volume":"46","author":"Lorenzetti","year":"2014","journal-title":"Ann Med"},{"key":"10.1016\/j.autrev.2025.103758_bb0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3899\/jrheum.140102","article-title":"Adalimumab, etanercept, infliximab, and the risk of TB: data from clinical trials, national registries, and postmarketing surveillance","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"issue":"3","key":"10.1016\/j.autrev.2025.103758_bb0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/keh483","article-title":"Anti-TNF-alpha therapies: they are all the same (aren\u2019t they?)","volume":"44","author":"Mpofu","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2025.103758_bb0070","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12664-022-01252-5","article-title":"Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: a real-world cohort analysis","volume":"41","author":"Kumar","year":"2022","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.autrev.2025.103758_bb0075","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20930116","article-title":"TB and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors","volume":"12","author":"Evangelatos","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103758_bb0080","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"TB and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2025.103758_bb0085","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/1756-185X.13853","article-title":"Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: a post hoc analysis of efficacy and safety in phase 3 and long-term extension studies over 7 years","volume":"23","author":"Chopra","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2025.103758_bb0090","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/17474124.2022.2106216","article-title":"Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective","volume":"16","author":"Mishra","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12664-023-01507-9","article-title":"Tofacitinib use in ulcerative colitis: an expert consensus for day-to-day clinical practice","volume":"43","author":"Banerjee","year":"2024","journal-title":"Indian J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"9894","key":"10.1016\/j.autrev.2025.103758_bb0105","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.autrev.2025.103758_bb0110","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2025.103758_bb0115","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/acr.22645","article-title":"Maintenance of clinical efficacy and radiographic benefit through two years of Ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial","volume":"67","author":"Kavanaugh","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.autrev.2025.103758_bb0120","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10067-017-3953-6","article-title":"Effectiveness and safety of ustekinumab in na\u00efve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study","volume":"37","author":"Chimenti","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"20","key":"10.1016\/j.autrev.2025.103758_bb0125","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2025.103758_bb0130","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/rheumatology\/key023","article-title":"Results from the British Society for Rheumatology biologics register for rheumatoid arthritis","volume":"57","author":"Ghosh","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/ibd\/izad032","article-title":"Risk of TB and hepatitis B reactivation in patients with Crohn\u2019s disease on Ustekinumab: a Nationwide real-world study","volume":"30","author":"Liu","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.autrev.2025.103758_bb0140","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jaad.2019.12.033","article-title":"Ustekinumab does not increase TB risk: results from a national database in South Korea","volume":"82","author":"Cho","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103758_bb0145","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"McInnes","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103758_bb0150","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/jdv.15653","article-title":"Safety of selective IL-23p19 inhibitors for the treatment of psoriasis","volume":"33","author":"Crowley","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103758_bb0155","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103758_bb0160","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/17474124.2023.2295496","article-title":"Risankizumab to treat moderately to severely active Crohn\u2019s disease in adults: an evaluation of trials and data","volume":"17","author":"Johnson","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jgh.16358","article-title":"Efficacy and safety of risankizumab for Crohn\u2019s disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies","volume":"39","author":"Gao","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2025.103758_bb0170","article-title":"Real-world effectiveness and safety of Risankizumab in patients with moderate to severe multirefractory Crohn\u2019s disease: a Belgian multicentric cohort study","volume":"12","author":"Alsoud","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"26","key":"10.1016\/j.autrev.2025.103758_bb0175","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis [published correction appears in N Engl J med. 2023 Aug 24;389(8):772]","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103758_bb0180","article-title":"Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study [published correction appears in Inflamm Bowel Dis. 2024 Apr 27;:]","author":"Sands","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"Issue Supplement_1","key":"10.1016\/j.autrev.2025.103758_bb0185","doi-asserted-by":"crossref","first-page":"i308","DOI":"10.1093\/ecco-jcc\/jjad212.0176","article-title":"P046 Real-world data on the treatment with Mirikizumab in a mostly biological-experienced Ulcerative colitis cohort","volume":"18","author":"Lande","year":"2024","journal-title":"J Crohn\u2019s and Colitis"},{"key":"10.1016\/j.autrev.2025.103758_bb0190","article-title":"Altered IL-6 signalling and risk of TB disease: a meta-analysis and Mendelian randomisation study. Preprint","author":"Hamilton","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.autrev.2025.103758_bb0195","first-page":"11","article-title":"Opportunistic infections in rheumatoid arthritis patients exposed to biologic PMID: 20436162 Rahman P, Inman RD, El-Gabalawy H, Krause DO. Pathophysiology and pathogenesis of immune-mediated inflammatory diseases: commonalities and differences","volume":"85","author":"Rutherford","year":"2010","journal-title":"J Rheumatol Suppl"},{"issue":"12","key":"10.1016\/j.autrev.2025.103758_bb0200","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1136\/ard.2011.151092","article-title":"Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients","volume":"70","author":"Koike","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0205","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2217\/imt-2017-0075","article-title":"A review of sarilumab for the treatment of rheumatoid arthritis","volume":"10","author":"Lee","year":"2018","journal-title":"Immunotherapy"},{"issue":"10","key":"10.1016\/j.autrev.2025.103758_bb0210","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/art.39249","volume":"67","author":"Weinblatt","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103758_bb0215","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/annrheumdis-2017-212496","article-title":"Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-na\u00efve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study","volume":"77","author":"Taylor","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2025.103758_bb0220","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1038\/cti.2017.34","article-title":"Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium TB infections","volume":"6","author":"Kamm\u00fcller","year":"2017","journal-title":"Clin Transl Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0225","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.autrev.2025.103758_bb0230","doi-asserted-by":"crossref","first-page":"e0225112","DOI":"10.1371\/journal.pone.0225112","article-title":"The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies","volume":"14","author":"Wu","year":"2019","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.autrev.2025.103758_bb0235","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/acr.23738","article-title":"Safety of Ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0240","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjd.17604","article-title":"Prevalence and outcome of latent TB in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis","volume":"181","author":"Romiti","year":"2019","journal-title":"Br J Dermatol"},{"issue":"24","key":"10.1016\/j.autrev.2025.103758_bb0245","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2025.103758_bb0250","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-219406","article-title":"Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial","volume":"80","author":"Wei","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2025.103758_bb0255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13555-016-0121-x","article-title":"Brodalumab for the treatment of psoriasis: a review of phase III trials","volume":"6","author":"Farahnik","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"10.1016\/j.autrev.2025.103758_bb0260","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kes365","article-title":"The effects of rituximab therapy on released interferon-\u03b3 levels in the QuantiFERON assay among RA patients with different status of Mycobacterium TB infection","volume":"52","author":"Chen","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103758_bb0265","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3899\/jrheum.140103","article-title":"TB risk in patients treated with non-anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) targeted biologics and recently licensed TNF-\u03b1 inhibitors: data from clinical trials and national registries","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"issue":"6","key":"10.1016\/j.autrev.2025.103758_bb0270","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2025.103758_bb0275","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"10.1016\/j.autrev.2025.103758_bb0280","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2025.103758_bb0285","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1212\/NXI.0000000000000839","article-title":"Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS","volume":"7","author":"Harris","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10383","key":"10.1016\/j.autrev.2025.103758_bb0290","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies [published correction appears in Lancet. 2023 Mar 25;401(10381):1000]","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.autrev.2025.103758_bb0295","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management","volume":"5","author":"Epstein","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.autrev.2025.103758_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102450","article-title":"A case report with tuberculous meningitis during fingolimod treatment","volume":"46","author":"K\u00f6seo\u011flu","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0305","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/apt.16952","article-title":"Review article: latent TB in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management","volume":"56","author":"Fehily","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0310","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4049\/jimmunol.0903856","article-title":"Understanding latent tuberculosis: a moving target","volume":"185","author":"Lin","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103758_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1046306","article-title":"Regional risk of TB and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review","volume":"14","author":"Jahnich","year":"2023","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103758_bb0320","doi-asserted-by":"crossref","first-page":"340","DOI":"10.14309\/ajg.0000000000000527","article-title":"Risk of TB in patients with inflammatory bowel disease on infliximab or adalimumab is dependent on the local disease burden of TB: a systematic review and Meta-analysis","volume":"115","author":"Kedia","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103758_bb0325","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/apt.16839","article-title":"Stringent screening strategy significantly reduces reactivation rates of TB in patients with inflammatory bowel disease on anti-TNF therapy in TB endemic region","volume":"55","author":"Kumar","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.autrev.2025.103758_bb0330","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CM9.0000000000001948","article-title":"Risk of TB in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials","volume":"135","author":"Ji","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"10.1016\/j.autrev.2025.103758_bb0335","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jmii.2013.03.005","article-title":"Risk of TB infection in anti-TNF-\u03b1 biological therapy: from bench to bedside","volume":"47","author":"Xie","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"10.1016\/j.autrev.2025.103758_bb0340","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S2213-2600(24)00085-7","article-title":"New framework to define the spectrum of tuberculosis","volume":"12","author":"Dheda","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.autrev.2025.103758_bb0345","doi-asserted-by":"crossref","first-page":"e830","DOI":"10.1093\/cid\/ciaa1402","article-title":"Subclinical tuberculosis disease-a review and analysis of prevalence surveys to inform definitions, burden, associations, and screening methodology","volume":"73","author":"Frascella","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.autrev.2025.103758_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(24)00028-6","article-title":"Classification of early TB states to guide research for improved care and prevention: an international Delphi consensus exercise","author":"Coussens","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"02","key":"10.1016\/j.autrev.2025.103758_bb0355","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-0043-1760741","article-title":"Evidence-based commentary: testing and treating Latent TB before starting biologics and small molecules in patients with inflammatory bowel disease","volume":"12","author":"Kakadiya","year":"2022","journal-title":"J Gastrointest Infect"},{"key":"10.1016\/j.autrev.2025.103758_bb0360","series-title":"Global tuberculosis report 2024","year":"2024"},{"issue":"2","key":"10.1016\/j.autrev.2025.103758_bb0365","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01959-2019","article-title":"International Atomic Energy Agency Extra-pulmonary TB Consortium. PET\/CT features of extrapulmonary tuberculosis at first clinical presentation: a cross-sectional observational 18F-FDG imaging study across six countries","volume":"55","author":"Bomanji","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2025.103758_bb0370","series-title":"Infection: Updated and consolidated guidelines for programmatic management","author":"Latent","year":"2018"},{"issue":"6","key":"10.1016\/j.autrev.2025.103758_bb0375","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14787210.2018.1483238","article-title":"Preventive therapy for TB in rheumatological patients undergoing therapy with biological drugs","volume":"16","author":"Goletti","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2","key":"10.1016\/j.autrev.2025.103758_bb0380","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of TB in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.autrev.2025.103758_bb0385","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1473-3099(19)30059-3","article-title":"Latent tuberculosis infection: diagnostic tests and when to treat","volume":"19","author":"Petersen","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.autrev.2025.103758_bb0390","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1473-3099(20)30276-0","article-title":"Interferon-\u03b3 release assays or tuberculin skin test for detection and management of latent TB infection: a systematic review and meta-analysis","volume":"20","author":"Zhou","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103758_bb0395","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and Management of Infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103758_bb0400","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1378\/chest.07-2193","article-title":"The effect of previous tuberculin skin test on the follow-up examination of whole-blood interferon-gamma assay in the screening for latent TB infection","volume":"133","author":"Choi","year":"2008","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.autrev.2025.103758_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188631","article-title":"Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: a latent-class analysis","volume":"12","author":"Doan","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2025.103758_bb0410","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3899\/jrheum.140099","article-title":"Performance of the tuberculin skin test and interferon-\u03b3 release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches","volume":"91","author":"Goletti","year":"2014","journal-title":"J Rheumatol Suppl"},{"issue":"7","key":"10.1016\/j.autrev.2025.103758_bb0415","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/ecco-jcc\/jjx022","article-title":"Early tuberculin skin test for the diagnosis of Latent TB infection in patients with inflammatory bowel disease","volume":"11","author":"Taxonera","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"4","key":"10.1016\/j.autrev.2025.103758_bb0420","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S2213-2600(16)30436-2","article-title":"Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon \u03b3 release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial","volume":"5","author":"Ruhwald","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.autrev.2025.103758_bb0425","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/diagnostics12020453","article-title":"Diagnostic value of interferon-gamma release assays for tuberculosis in the immunocompromised population","volume":"12","author":"Yang","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0430","article-title":"Comparing the diagnostic performance of QuantiFERON-TB gold plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.autrev.2025.103758_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.672894","article-title":"Tuberculosis risk stratification of psoriatic patients before anti-TNF-\u03b1 treatment","volume":"12","author":"Benhadou","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103758_bb0440","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.02443-21","article-title":"Optimal detection of Latent Mycobacterium tuberculosis infection by combined heparin-binding hemagglutinin (HBHA) and early secreted antigenic target 6 (ESAT-6) whole-blood interferon gamma release assays","volume":"60","author":"Dirix","year":"2022","journal-title":"J Clin Microbiol"},{"issue":"13","key":"10.1016\/j.autrev.2025.103758_bb0445","article-title":"Immuno-diagnosis of active tuberculosis by a combination of cytokines\/chemokines induced by two stage-specific mycobacterial antigens: a pilot study in a low TB incidence country","volume":"10","author":"Dirix","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103758_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254571","article-title":"Mycobacterial heparin-binding hemagglutinin (HBHA)-induced interferon-\u03b3 release assay (IGRA) for discrimination of latent and active tuberculosis: a systematic review and meta-analysis","volume":"16","author":"Tang","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2025.103758_bb0455","article-title":"Abnormalities suggestive of latent TB infection on chest radiography; how specific are they?","volume":"15","author":"Uzorka","year":"2019","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"7","key":"10.1016\/j.autrev.2025.103758_bb0460","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz313","article-title":"Radiological signs of Latent TB on chest radiography: a systematic review and Meta-analysis","volume":"6","author":"Uzorka","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103758_bb0465","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103758_bb0470","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.3390\/jcm12062127","article-title":"Analysis of a combined HBHA and ESAT-6-interferon-\u03b3-release assay for the diagnosis of tuberculous lymphadenopathies","volume":"12","author":"Mascart","year":"2023","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.autrev.2025.103758_bb0475","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.crad.2023.04.014","article-title":"CT in the detection of latent TB: a systematic review","volume":"78","author":"Moore","year":"2023","journal-title":"Clin Radiol"},{"issue":"9979","key":"10.1016\/j.autrev.2025.103758_bb0480","first-page":"1799","article-title":"For WHO\u2019s global TB Programme","volume":"385","author":"Uplekar","year":"2015","journal-title":"WHO\u2019s new end TB strategy Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0485","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1186\/s12889-024-19495-6","article-title":"FDG-PET-CT as an early detection method for tuberculosis: a systematic review and meta-analysis","volume":"24","author":"Yayan","year":"2024","journal-title":"BMC Public Health"},{"issue":"10","key":"10.1016\/j.autrev.2025.103758_bb0490","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/nm.4161","article-title":"Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography","volume":"22","author":"Esmail","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103758_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2023.07.003","article-title":"Risk of progression to active TB for indeterminate interferon-gamma release assay in immunocompromised individuals: a systematic review and meta-analysis","author":"Zhou","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.autrev.2025.103758_bb0500","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy184","article-title":"Risk Factors for Indeterminate Outcome on Interferon Gamma Release Assay in Non-US-Born Persons Screened for Latent TB Infection","volume":"5","author":"Sharninghausen","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"13","key":"10.1016\/j.autrev.2025.103758_bb0505","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.3390\/jcm11133915","article-title":"Performance of Screening Strategies for Latent TB Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU","volume":"11","author":"Riestra","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.autrev.2025.103758_bb0510","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3899\/jrheum.081042","article-title":"Preventing TB flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-\u03b1 inhibitors in India \u2014 an audit report","volume":"36","author":"Malaviya","year":"2009","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103758_bb0515","doi-asserted-by":"crossref","first-page":"588","DOI":"10.5217\/ir.2018.00023","article-title":"High risk of TB during infliximab therapy despite TB screening in inflammatory bowel disease patients in India","volume":"16","author":"Agarwal","year":"2018","journal-title":"Intest Res"},{"issue":"10","key":"10.1016\/j.autrev.2025.103758_bb0520","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ecco-jcc\/jjw129","article-title":"Negative screening does not rule out the risk of TB in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID cohort","volume":"10","author":"Abitbol","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"8","key":"10.1016\/j.autrev.2025.103758_bb0525","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/ecco-jcc\/jjy057","article-title":"A prospective study to monitor for TB during anti-tumour necrosis factor therapy in patients with inflammatory bowel disease and immune-mediated inflammatory diseases","volume":"12","author":"Lee","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103758_bb0530","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent TB infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of Latent TB infection: recommendations from the national TB controllers association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"10.1016\/j.autrev.2025.103758_bb0540","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/apt.16130","article-title":"Targeted versus universal TB chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a TB endemic region","volume":"53","author":"Ye","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2025.103758_bb0545","doi-asserted-by":"crossref","first-page":"16240","DOI":"10.1038\/s41598-023-43310-8","article-title":"Efficacy of anti-TB drugs for the treatment of latent TB infection: a systematic review and network meta-analysis","volume":"13","author":"Yoopetch","year":"2023","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.autrev.2025.103758_bb0550","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ccm.2019.07.008","article-title":"Treatment of Latent TB infection-an update","volume":"40","author":"Huaman","year":"2019","journal-title":"Clin Chest Med"},{"issue":"4","key":"10.1016\/j.autrev.2025.103758_bb0555","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of Latent TB infection: an updated network Meta-analysis","volume":"167","author":"Zenner","year":"2017","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.autrev.2025.103758_bb0560","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(19)30575-4","article-title":"Adverse events in adults with latent TB infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials","volume":"20","author":"Campbell","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.autrev.2025.103758_bb0565","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antiTB therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.autrev.2025.103758_bb0570","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0041-3879(80)90038-0","article-title":"Pyridoxine supplementation during isoniazid therapy","volume":"61","author":"Snider","year":"1980","journal-title":"Tubercle"},{"key":"10.1016\/j.autrev.2025.103758_bb0575","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.1038\/s41598-020-63156-8","article-title":"Adherence to nine-month isoniazid for latent TB infection in healthcare workers: a prospective study in a tertiary hospital","volume":"10","author":"Chung","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.autrev.2025.103758_bb0580","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12664-023-01343-x","article-title":"Evidence-based approach to diagnosis and management of abdominal TB","volume":"42","author":"Jha","year":"2023","journal-title":"Indian J Gastroenterol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103758_bb0585","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000493","article-title":"Prophylactic Antitubercular therapy is associated with accelerated disease progression in patients with Crohn\u2019s disease receiving anti-TNF therapy: a retrospective multicenter study","volume":"13","author":"Liu","year":"2022","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.autrev.2025.103758_bb0590","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3899\/jrheum.140101","article-title":"Diagnosis of latent TB and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations","volume":"91","author":"Iannone","year":"2014","journal-title":"J Rheumatol Suppl"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2025.103758_bb0595","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults [published correction appears in gut. 2021 Apr;70(4):1]","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T15:12:51Z","timestamp":1739718771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225000187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":119,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1568997225000187"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103758","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment and management for latent tuberculosis before advanced therapies for immune-mediated inflammatory diseases: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103758","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103758"}}